<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779895</url>
  </required_header>
  <id_info>
    <org_study_id>12.18.MET</org_study_id>
    <nct_id>NCT01779895</nct_id>
  </id_info>
  <brief_title>Probiotic Administration and Perennial Allergic Rhinitis</brief_title>
  <official_title>Effect of Probiotic Lactobacillus Paracasei NCC2461 on House Dust Mite Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of a probiotic strain in improving the&#xD;
      quality of life in adult subjects suffering from perennial allergic rhinit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life, measured by a validated mini rhinoconjunctivitis quality of life questionnaire (MiniRQLQ)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Compared over 8 weeks between the two treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of pro-inflammatory cytokines in ex-vivo stimulated whole blood cells</measure>
    <time_frame>Measured 3 times: at the start of product intake, after 4 weeks and after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophil activation in ex-vivo stimulated whole blood cells</measure>
    <time_frame>Measured 3 times: at the start of product intake, after 4 weeks and after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Medication score</measure>
    <time_frame>Measured weekly for the 8 weeks of product intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Specific Immunoglobulin E</measure>
    <time_frame>Measured 2 times: at the start of product intake and after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>during the 8 weeks of product intake</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>NCC2461</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic blended in maltodextrin powder to be taken daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus paracasei probiotic strain</intervention_name>
    <arm_group_label>NCC2461</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 20-65 years old&#xD;
&#xD;
          -  Confirmed allergy (allergic rhinitis) to dust mite for more than 2 years, as&#xD;
             determined by anamnesis and by a miniRQLQ of ≥ 1&#xD;
&#xD;
          -  Positive Skin prick testing measure greater than 3mm wheal diameter to the&#xD;
             dermatophagoides pteronyssinus species of house dust mite extract&#xD;
&#xD;
          -  Body Mass Index 19-29&#xD;
&#xD;
          -  Having obtained his/her informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Allergy to any food or medication&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Family history of congenital immunodeficiency or chronic consumption (more than one&#xD;
             week at Screening) of immunosuppressive or anti-inflammatory treatments&#xD;
&#xD;
          -  Ongoing treatment with antibiotics or undergoing allergen immunotherapy at Screening&#xD;
&#xD;
          -  Consumption of probiotic and other dietary nutritional interventions&#xD;
&#xD;
          -  More than 2 drinks/day alcohol consumption or use of illicit drugs&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Subjects with expected low compliance&#xD;
&#xD;
          -  Blood donation in the past month or planning to donate blood until a month after the&#xD;
             end of the study&#xD;
&#xD;
          -  Currently participating or having participated in another interventional clinical&#xD;
             trial during the last four weeks prior to the beginning the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nestlé Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic Unit, Nestlé Research Centre</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dust mite</keyword>
  <keyword>Perennial allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

